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Abstract 
A monoclonal antibody to the human epidermal growth factor (EGF) receptor was conjugated with polylysine and the resulting conjugate was 
affinity-linked with DNA (gene). This novel gene delivery system utiliies receptor-mediated ndocytosis and would be especially suitable for gene 
therapy for EGF receptor-overproducing squamous cell carcinomas. 
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1. Introduction 2. Materials and methods 
In recent years, there has been a substantial interest in 
developing a delivery system of foreign genes into target 
cells for therapeutic purposes. These gene delivery sys- 
tems mainly utilize retrovirus and adenovirus vectors 
through their infective abilities [ 11. 
2.1, Cell and cell culture 
A squamous carcinoma cell line, NA (from Dr. K. Rikimura, Tokyo 
Medical Dental Univ., Tokyo, Japan) [7,8] and a human lung 
adenocarcinoma cell line, AS49 were maintained in plastic dishes con- 
taining Dulbecco’s modified Eagle’s medium (DMEM, Gibco) plus 
10% fetal calf serum at 37’C and 5% CO,. 
For the gene therapy of cancer, there are successful 
cases such as the cure of melanoma by introducing the 
tumor necrosis factor (TNF) gene into tumor infiltrating 
bone marrow cells 121. In this case, bone marrow cells 
isolated from patients are treated with DNA in vitro by 
the calcium-phosphate precipitation method and electro- 
poration and returned into patient blood. However, 
there is little way to direct gene transfer into specific 
target cells. If such gene delivery systems are developed, 
it would be extremely beneficial for cancer therapy. 
2.2. Monoclonal antibody(B4G7) against the human EGF receptor 
Murine monoclonal antibodies (MoAbs) of IgG2 type that im- 
munoreact with the human low-affinity type EGF receptors were pro- 
duced by a hybridoma cell line B4G7 [3]. 
2.3. Plasmid preparation 
The pSV2 CAT plasmid DNA [9] was grown in E. coli, isolated, and 
purified according to the method of Bimboim and Doly [lo]. Purity was 
confirmed by 1% agarose gel electrophoresis demonstrating the absence 
of bacterial cellular DNA. 
2.4. ModiJication of B4G7 with N-succinimidyl-3-(2-pyridyldithio) 
Mouse monoclonal antibody (MoAb) B4G7 is an IgG 
class 2 and binds specifically to a protein portion of the 
EGF receptor [3]. This MoAb is uniquely internalized 
through endocytic mechanisms of EGF receptors and 
therefore it has been successfully used to construct an 
immunotoxin which targets EGF receptor-overproduc- 
ing cancer cells [4-61. Thus, this MoAb delivers toxic 
proteins into human cells. In this paper, we utilized 
B4G7 antibody as a vehicle to deliver a DNA segment 
(gene) into human cancer cells through EGF receptor. 
propionate (SPDP) 
B4G7 murine MoAb (1 mg/ml) in 100 mM potassium phosphate 
buffer, pH 8.0, EDTA (0.5 mM) was mixed with a 17-fold molar excess 
of SPDP added from a freshly made solution (10 mM) in ethanol. The 
mixture was incubated at 37’C for 30 min. Reactions were terminated 
by gel filtration at 4°C through columns of Sephadex G-25 equilibrated 
with 200 mM HEPES buffer, pH 7.9, containing EDTA (0.5 mM). 
About three dithiopyridyl groups were incorporated per molecule of 
antibody, measured as described previously [4,11], and then diluted 
with IO-fold volume of HBS buffer (20 mM HEPES pH 7.3, 150 mM 
NaCI) at 4”C, ultraconcentrated by filtration (Amicon), and filtered 
through 0.22-mm membranes (Millipore Corp.) 
2.5. Modification of polylysine with 2-iminothiolane 
*Corresponding author. Fax: (81) (3) 3351 2370. 
Abbreviations: EGF, epidermal growth factor; MoAb, monoclonal an- 
tibody; CAT, chloramphenicol acetyltransferase; SPDP, N-succin- 
imidyl 3-(2-pyridyldithio) propionate; TNF, tumor necrosis factor, 3- 
AcCM; 3-acethyl chloramphenicol; CM, chloramphenicol; EBSS, 
Earle’s balanced salt solution. 
Polylysine (1 mg/ml) in water was mixed with 0.5 M triethanolamine- 
HCI buffer, pH 8.0, and 0.1 M EDTA. The final concentration of 
triethanolamine and EDTA were 60 mM and 1 mM, respectively. The 
solution was then degassed and kept under nitrogen at O”C, then treated 
with 2-iminothiolane (1 mM) at 0°C for 90 min under nitrogen. The 
excess reagent was removed by gel filtration at 4°C on a column of 
Sephadex G-25 equilibrated with 5 mM bis-tris/acetate buffer, pH 5.8, 
containing 50 mM NaCl and 1 mM EDTA. The pH of modiied poly- 
lysine solution was raised to 7.0 by adding 1110 volume of 0.5 M 
triethanolamine-HCl buffer, pH 8.0. 
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2.6. Conjugation of modiJied B4G7 with modified polylysine 
Modified B4G7 in HBS buffer was mixed with an equal weight 
(about 5-fold molar excess) of modified polylysine. The mixture was 
kept under nitrogen at 4°C for 20 h. Finally, 2 mM iodoacetamide was 
added to block any remaining free sulfbydryl groups and incubation 
continued for 1 h at 25°C. 
2.7. Purification of B4G7-polylysine conjugate 
Conjugates were isolated by cation-exchange chromatography on a 
Mono S HR 5/5 column (Pharmacia) using a gradient from 80% A/20% 
B buffer to 100% B buffer (A, 50 mM HEPES pH 7.9; B, A + 3 M NaCl) 
[12]. The product fractions, eluting between 1.65 M and 2 M salt 
(NaCl), were dialyzed against HBS, and then filtered through 0.22~pm 
membranes to ensure that conjugates to be used did not contain precip- 
itates. 
2.8. Preparation of B4G7-polylysinelDNA complex and assay for DNA 
delivery 
Complex formation of the DNA to the polylysine conjugated mono- 
clonal antibody (B4G7) was accomplished as described by Curie1 et al. 
[12]. After incubation at room temperature for 30 min, the complex was 
applied to lo-cm tissue culture dishes containing 5 x 10’ NA cells grown 
in DMEM, 10% FCS (37°C 5% COr). The cells were incubated at 37°C 
for 24 h, washed by 10% FCSIDMEM, and then maintained for 60 h. 
To evaluate reporter gene expression, cell lysates were prepared as 
described by Wu et al. [13], and assayed for chloramphenicol ace- 
tyltransferase activity as described by Gorman et al. [9]. In brief, cell 
extracts were incubated at 37°C with [“‘C]chloramphenicol (DuPont 
New England Nuclear) in 0.25 M Tris-HCl, pH 7.5, to which was added 
acetyl coenzyme A (4 mM) for 60 min. A thin layer chromatography 
plate was autoradiographed using Imaging plate (Fuji Photo Film) at 
room temperature for 2 h, and analyzed by Fujix BAS2000 system (Fuji 
Photo Film). 
2.9. Binding assay and competitive inhibition assay 
The B4G7 MoAb was labeled with ‘*‘I using Iodobeads [14]. 
[‘?]B4G7 binding was assayed as described previously [15]. Confluent 
cell cultures grown in 24-well plastic dishes were washed twice with 1 
ml of ice-cold EBSS buffer on ice and treated with [‘r51]B4G7 (approx. 
30,000 cpm) with various concentrations of unlabeled B4G7, B4G7- 
polylysine conjugate and B4G7_polylysine/DNA complex in 1 ml of 
EBSS buffer for 2 h [15]. Then the cells were washed three times with 
1 ml of EBSS buffer and solubilized in 1 N NaOH. The cell-associated 
radioactivity was determined in a Beckman 5500 gamma counter. 
3. Results 
B4G7 antibody and polylysine were activated sepa- 
rately with SPDP and 2-iminothiolane, and mixed to- 
gether to form a conjugate via disulfide bonds. The re- 
sulting B4G7-polylysine conjugate was purified by 
Mono S column chromatography. This conjugate was 
then mixed with pSV2 CAT plasmid DNA to form an 
affinity complex. The resulting conjugate/DNA complex 
migrates differently from DNA itself under agarose gel 
electrophoresis (Fig. 1). The DNA/conjugate complex is 
formed in proportion to the DNA concentration. Since 
positive charges of polylysine interfere with the ethidium 
bromide staining of DNA, the complex unsaturated with 
DNA is not visible. The conjugate can be saturated with 
DNA and then becomes visible at the top of the gel. The 
DNA/conjugate complex apparently binds to the EGF 
receptor because they inhibited the binding of [1251]B4G7 
to the cells (Fig. 2). Then the DNA/conjugate complex 
was added into a culture of NA cells overexpressing EGF 
receptors and CAT activity was measured after 60 h. 
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Fig. 1. Agarose gel electrophoresis of B4G7-polylysine/DNA complex. 
B4G7-polylysine conjugate (0.2 pug) was mixed with various amounts 
of pSV2 CAT plasmid DNA (0.2, 1, or 2 pg) and electrophoresed on 
agarose gel. The presence of DNA was visualized with ethidium bro- 
mide under UV illumination. DNA markers are I DNA digested with 
BstPI 
Significant CAT activity was expressed in these cells, 
whereas no CAT activity was detected when cells were 
treated with DNA alone or a mixture of antibody, poly- 
lysine and DNA (Fig. 3A). The CAT gene expression 
was detectable 12 h after transfection and increased until 
72 h (data not shown). CAT activity was increased when 
the conjugate carrying 2-fold DNA was used for trans- 
fection (Fig. 3B). Thus, CAT gene DNA was delivered 
with B4G7 antibody through EGF receptors and ex- 
pressed in the transfected cells. 
4. Discussion 
We have described a novel gene delivery system using 
the EGF receptor-specific monoclonal antibody. This 
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Fig. 2. Competitive inhibition of [‘*‘I]B4G7 binding by B4G7-polyly- 
sine/DNA complex. Binding of [“‘I]B4G7 antibody to A549 cells was 
measured in the presence of increasing amounts of B4G7-polylysine 
conjugate or B4G7-polylysine/DNA complex. 
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Fig. 3. CAT gene transfection by B4G7-polylysine/DNA complex. (A) 
Delivery of CAT gene through complex formation; NA cells were 
incubated with DNA only, a mixture of B4G7, polylysine and DNA, 
and B4G7-polylysine/DNA complex, respectively. CAT activity was 
detected as a production of 3-AcCM. (B) Dose dependent expression; 
NA cells were treated with complex of B4G7-polylysine (10 pg) with 
DNA (10 pg or 20 pg). 
system utilizes a natural cellular mechanism which is 
receptor-mediated endocytosis and therefore little dam- 
age is given to the cells as compared to conventional gene 
transfer systems uch as calcium-phosphate method and 
electroporation. Furthermore, the present system can 
avoid a potential problem of viral gene expression when 
a virus was used as a gene transfer vehicle. Previously, 
Wu et al. reported the gene delivery system using an 
asialoglycoprotein as a vehicle to target liver cells [ 131. 
Our system is unique because a specific MoAb was used 
as a vehicle to target only the EGF receptor-expressing 
cells among various types of cells. In this regard, EGF 
receptor-overexpressing tumor cells like those derived 
from squamous cell carcinomas can be targeted as being 
successful in delivering toxic proteins [46]. In this paper, 
CAT gene was used as a reporter gene and its incorpora- 
tion and expression was sufficient. Any genes can be 
delivered into target cells because attachment of DNA to 
the polylysine portion of conjugate is affinity binding. 
We are now using this system to develop gene therapy 
not only for EGF receptor-overproducing squamous cell 
carcinomas but also for certain genetic diseases. 
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